ClinicalTrials.gg
RecruitingNCT06712641AGESUpdated Oct 28, 2026

Aminoglycosides in Early Sepsis

A Phase 4 interventional study of Gentamicin + narrow spectrum betalactam and Cefotaxime in Sepsis, sponsored by University Hospital, Akershus. Recruiting at 15 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by University Hospital, Akershus · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 28, 2026Site recruiting status changed10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Sepsis with a site in Norway — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Norway.

Started
2026
with 1 other
Phase 4
3 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
University Hospital, Akershus

Among the 12 studies in Sepsis with a site in Norway, this one is one of 2 that started in 2026, is one of 3 in phase 4, and was the 11th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 12 studies in Sepsis with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Sepsis with a site in Norway, or all of them as a file.
02

Study summary

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.

In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • sepsis
  • antibiotics
  • aminoglycosides
  • cephalosporins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized
  • Adults 18 year or older
  • Clinical suspicion of community acquired sepsis with indication for empirical antibiotic therapy
  • National Early Warning Score 2 (NEWS2) ≥ 5
  • Signed must be obtained and documented according to ICH GCP, and national/local regulations

Exclusion criteria

Exclusion Criteria:

  • Established chronic kidney failure ( \< 30 ml/min/1.73m2)
  • Presentation with septic shock with multiorgan failure
  • Suspicion of condition necessitating specific antimicrobial therapy (e.g. atypical pneumonia, fungal infection, parasitic infection, mycobacterial infection)
  • Current or recent use of nephrotoxic drugs (e.g cisplatin within previous 2 months)
  • Suspected or confirmed carrier of extended spectrum betalactamase (ESBL) producing bacteria, methicillin-resistant Staphylococcus aureus (MRSA), or other drug-resistant microbes necessitating specific antimicrobial therapy
  • Multiple myeloma
  • Renal transplantation
  • Renal replacement therapy
  • Myasthenia gravis
  • Known to any of the study drugs
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,900 participants (estimated)

Study arms

  • Active comparator
    Gentamicin + narrow spectrum betalactam

    Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)

    Drug: Gentamicin + narrow spectrum betalactam

  • Active comparator
    Cefotaxime or piperacillin-tazobactam

    Empirical therapy for suspected community-acquired sepsis with broad spectrum betalactam (either one of cefotaxime or piperacillin-tazobactam)

    Drug: Cefotaxime · Drug: Piperacillin-tazobactam

Interventions

  • DrugGentamicin + narrow spectrum betalactam

    Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)

  • Empirical therapy for suspected community-acquired sepsis with cefotaxime

  • DrugPiperacillin-tazobactam

    Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam

06

What researchers measure

Primary outcomes

  1. 30-day mortality

    All-cause mortality up to 30 days after randomization

    Time frame: Up to 30 days after randomization

  2. 30-day acute kidney injury

    Any acute kidney injury up to 30 days after randomization

    Time frame: Up to 30 days after randomization

Secondary outcomes

  1. In-hospital mortality

    All-cause mortality during index hospitalization

    Time frame: During index hospitalization (commonly up to 30 days)

  2. Duration of hospital stay

    Duration of index hospitalization (days)

    Time frame: During index hospitalization (commonly up to 30 days)

  3. Duration of intensive care stay

    Duration of stay in intensive care unit (days)

    Time frame: During index hospitalization (commonly up to 30 days)

  4. Duration of ventilator therapy

    Duration of therapy with invasive mechanical ventilation (days)

    Time frame: During index hospitalization (commonly up to 30 days)

  5. Duration of vasopressor therapy

    Duration of therapy with vasoactive (vasopressor) (days)

    Time frame: During index hospitalization (commonly up to 30 days)

  6. Hospital readmissions

    Readmission after discharge from index hospitalization

    Time frame: Up to 30 days after discharge from index hospitalization

  7. Post-discharge mortality

    All-cause mortality after discharge from index hospitalization

    Time frame: Up to 30 days after discharge from index hospitalization

  8. Duration of antibiotic treatment

    Duration of antibiotic therapy during index hospitalization (days of therapy, DOT)

    Time frame: During index hospitalization (commonly up to 30 days)

07

Study locations

4 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The dataset used in this study is not publicly available, as the Data Protection Authority approval and patient consent do not allow for such publication. The study group welcomes initiatives for cooperation and data access may be granted upon application.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

Of 65 non-industry phase 4 interventional studies under Sepsis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 26 months is close to that.

Counting every sponsor, half of 66 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 2, 2024
StartActual
Apr 23, 2026
Primary completionEst.
Jun 2028
CompletionEst.
May 2033
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Haukeland University Hospital · Bergen, NorwayNot yet recruiting→Recruiting
  • Lovisenberg Diakonal Hospital · Oslo, NorwayNot yet recruiting→Recruiting
Show 10 added (10 Norway)
  • Ålesund Hospital, Helse Møre og Romsdal HF · Ålesund, Norway
  • Bodø Hospital Nordlandssykehuset HF · Bodø, Norway
  • Drammen Hospital, Vestre Viken HF · Drammen, Norway
  • Bærum Hospital, Vestre Viken Hospital Trust · Gjettum, Norway
  • Østfold Hospital Kalnes HF · Grålum, Norway
  • Nordmøre and Romsdal Hospital, Helse Møre og Romsdal HF · Hjelset, Norway
  • Ringerike Hospital, Vestre Viken Hospital Trust · Hønefoss, Norway
  • Sykehuset Telemark Skien · Skien, Norway
  • University Hospital of North Norway · Tromsø, Norway
  • Vestfold Hospital HF · Tønsberg, Norway
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    10 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Haukeland University Hospital · Bergen, NorwayNot yet recruiting→Recruiting
    • Lovisenberg Diakonal Hospital · Oslo, NorwayNot yet recruiting→Recruiting
    Show 10 added (10 Norway)
    • Ålesund Hospital, Helse Møre og Romsdal HF · Ålesund, Norway
    • Bodø Hospital Nordlandssykehuset HF · Bodø, Norway
    • Drammen Hospital, Vestre Viken HF · Drammen, Norway
    • Bærum Hospital, Vestre Viken Hospital Trust · Gjettum, Norway
    • Østfold Hospital Kalnes HF · Grålum, Norway
    • Nordmøre and Romsdal Hospital, Helse Møre og Romsdal HF · Hjelset, Norway
    • Ringerike Hospital, Vestre Viken Hospital Trust · Hønefoss, Norway
    • Sykehuset Telemark Skien · Skien, Norway
    • University Hospital of North Norway · Tromsø, Norway
    • Vestfold Hospital HF · Tønsberg, Norway
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06712641
Collaborators
Ullevaal University Hospital
Responsible party
Magnus Nakrem Lyngbakken (Professor, University Hospital, Akershus) — Principal investigator
First posted
Dec 2, 2024
Start date
Apr 23, 2026
Primary completion
Jun 2028 (estimated)
Completion
May 2033 (estimated)
Last update
Oct 28, 2026

Study contacts

Magnus N Lyngbakken, MD PhD
Contact
magnus.lyngbakken@medisin.uio.no
+4793408837
Kristian Tonby, MD PhD
Contact
kristian.tonby@medisin.uio.no
+4741550565

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefotaxime

Start the discussion